Epidaza (chidamide) / Chipscreen, Meiji Seika, HUYA Bioscience, Eisai, GNT Biotech  >>  Phase 1
Welcome,         Profile    Billing    Logout  

9 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Epidaza (chidamide) / Chipscreen
ChiCTR-ONC-12002283: Phase Ib Clinical Trial of Chidamide Combined With Paclitaxel and Carboplatin Chemotherapy in Patients with Advanced Non–Small-Cell Lung Cancer

Completed
1
18
 
Paclitaxel 175mg/m2 and Carboplatin AUC=5mg/ml·min once every 3 weeks Chidamide TIW escalated from 20mg
Cancer Hospital, Chinese Academy of Medical Sciences; Chipscreen Biosciences, Ltd., Chipscreen Biosciences, Ltd.
Advanced Non Small Cell Lung Cancer (NSCLC)
 
 
ChiCTR2000040043: A phase I clinical study of the safety, tolerability, pharmacokinetics and efficacy of Azacitidine for injection combined with Chidamide in patients with relapsed/refractory T-cell lymphoma

Not yet recruiting
1
17
 
Dose group 1: azacitidine 50mg/m2, iv, d1-7; Chidamide 20mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle ;Dose group 2: azacitidine 75mg/m2, iv, d1-7; Chidamide 20mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle ;Dose group 3: azacitidine 50mg/m2, iv, d1-7; Chidamide 30mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle ;Dose group 4: Azacytidine 75mg/m2, iv, d1-7; Chidamide 30mg, po, biw, taking the medicine for 3 weeks; 4 weeks as a cycle; ;RP2D
Tianjin Cancer Hospital; Tianjin Cancer Hospital, Tianjin Cancer Hospital
T cell lymphoma
 
 
CHIDA-01, NCT05338541: Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.

Recruiting
1
30
RoW
Tucidinostat and etoposide
Yizhuo Zhang
Neuroblastoma in Children
06/24
12/24
NCT05281276: Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)

Recruiting
1
12
RoW
chidamide, tucidinostat, HBI-8000, celecoxib, Celebrex
Taipei Medical University Shuang Ho Hospital
Metastatic Colorectal Cancer
12/24
12/24
NCT05659992: Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Recruiting
1
30
RoW
azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte
Chinese PLA General Hospital
Acute Myeloid Leukemia
01/24
01/24
ChiCTR2200065634: One arm open phase I clinical study of Venetoclax combined with CACAG regimen in the treatment of acute myeloid leukemia

Recruiting
1
30
 
1.azacytidine (75mg/m2/day, days 1 to 7). 2.cytarabine (75mg/m2 bid, days 1 to 5). 3.aclamycin (10mg/m2/day, day1,3,5). 4.Chidamide (30mg/day , days 0,3). 5.venetoclax (100mg day 1, 200 mg day 2, 400mg days 3 to 14 ). 6.granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery
Chinese PLA General Hospital; Chinese PLA General Hospital, Fully self-raised
acute myeloid leukemia
 
 
ChiCTR2200058569: Safety and efficacy of histone deacetylase inhibitors (chidamide) in combination with abiraterone in the treatment of metastatic castration-resistant prostate cancer (mCRPC): a single-arm, open phase, Ib clinical study study

Recruiting
1
 
Citabenamine (20mg) in combination with abiraterone ;Citabenamine (25mg) in combination with abiraterone ;Citabenamine (30mg) in combination with abiraterone
Sun Yat-sen University Cancer Center ; Sun Yat-sen University Cancer Center, Sun Yat-sen University Cancer Center
prostatic cancer
 
 
NCT05586841: Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Not yet recruiting
1
30
RoW
Dalpiciclib, SHR6390, Chidamide
Beijing 302 Hospital
HR+/HER2- Advanced Breast Cancer
11/24
11/25
ChiCTR2300067674: An Exploratory Study on Individualized Treatment of Chidamide Combined with Chemotherapy in Children with Acute Myeloid Leukemia

Not yet recruiting
1
9
 
Cladribine + Homoharringtonine + cytarabine + Granulocyte stimulating factor + Chidamide
Division of Pediatric Blood Diseases Center State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences; Division of Pediatric Blood Diseases Center State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, No
AML
 
 

Download Options